Cargando…

FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway

BACKGROUND: Radiotherapy resistance is the main cause of treatment failure in nasopharyngeal carcinoma (NPC), which leads to poor prognosis. It is urgent to elucidate the molecular mechanisms underlying radiotherapy resistance. METHODS: RNA-seq analysis was applied to five paired progressive disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Enni, Huang, Jiajia, Chen, Miao, Wu, Jiawei, Ouyang, Puyun, Wang, Xiaonan, Shi, Dingbo, Liu, Zhiqiao, Zhu, Wancui, Sun, Haohui, Yang, Shanshan, Zhang, Baoyu, Deng, Wuguo, Qiu, Huijuan, Xie, Fangyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945741/
https://www.ncbi.nlm.nih.gov/pubmed/36814284
http://dx.doi.org/10.1186/s12967-023-03986-y
_version_ 1784892199345848320
author Chen, Enni
Huang, Jiajia
Chen, Miao
Wu, Jiawei
Ouyang, Puyun
Wang, Xiaonan
Shi, Dingbo
Liu, Zhiqiao
Zhu, Wancui
Sun, Haohui
Yang, Shanshan
Zhang, Baoyu
Deng, Wuguo
Qiu, Huijuan
Xie, Fangyun
author_facet Chen, Enni
Huang, Jiajia
Chen, Miao
Wu, Jiawei
Ouyang, Puyun
Wang, Xiaonan
Shi, Dingbo
Liu, Zhiqiao
Zhu, Wancui
Sun, Haohui
Yang, Shanshan
Zhang, Baoyu
Deng, Wuguo
Qiu, Huijuan
Xie, Fangyun
author_sort Chen, Enni
collection PubMed
description BACKGROUND: Radiotherapy resistance is the main cause of treatment failure in nasopharyngeal carcinoma (NPC), which leads to poor prognosis. It is urgent to elucidate the molecular mechanisms underlying radiotherapy resistance. METHODS: RNA-seq analysis was applied to five paired progressive disease (PD) and complete response (CR) NPC tissues. Loss-and gain-of-function assays were used for oncogenic function of FLI1 both in vitro and in vivo. RNA-seq analysis, ChIP assays and dual luciferase reporter assays were performed to explore the interaction between FLI1 and TIE1. Gene expression with clinical information from tissue microarray of NPC were analyzed for associations between FLI1/TIE1 expression and NPC prognosis. RESULTS: FLI1 is a potential radiosensitivity regulator which was dramatically overexpressed in the patients with PD to radiotherapy compared to those with CR. FLI1 induced radiotherapy resistance and enhanced the ability of DNA damage repair in vitro, and promoted radiotherapy resistance in vivo. Mechanistic investigations showed that FLI1 upregulated the transcription of TIE1 by binding to its promoter, thus activated the PI3K/AKT signaling pathway. A decrease in TIE1 expression restored radiosensitivity of NPC cells. Furthermore, NPC patients with high levels of FLI1 and TIE1 were correlated with poor prognosis. CONCLUSION: Our study has revealed that FLI1 regulates radiotherapy resistance of NPC through TIE1-mediated PI3K/AKT signaling pathway, suggesting that targeting the FLI1/TIE1 signaling pathway could be a potential therapeutic strategy to enhance the efficacy of radiotherapy in NPC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03986-y.
format Online
Article
Text
id pubmed-9945741
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99457412023-02-23 FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway Chen, Enni Huang, Jiajia Chen, Miao Wu, Jiawei Ouyang, Puyun Wang, Xiaonan Shi, Dingbo Liu, Zhiqiao Zhu, Wancui Sun, Haohui Yang, Shanshan Zhang, Baoyu Deng, Wuguo Qiu, Huijuan Xie, Fangyun J Transl Med Research BACKGROUND: Radiotherapy resistance is the main cause of treatment failure in nasopharyngeal carcinoma (NPC), which leads to poor prognosis. It is urgent to elucidate the molecular mechanisms underlying radiotherapy resistance. METHODS: RNA-seq analysis was applied to five paired progressive disease (PD) and complete response (CR) NPC tissues. Loss-and gain-of-function assays were used for oncogenic function of FLI1 both in vitro and in vivo. RNA-seq analysis, ChIP assays and dual luciferase reporter assays were performed to explore the interaction between FLI1 and TIE1. Gene expression with clinical information from tissue microarray of NPC were analyzed for associations between FLI1/TIE1 expression and NPC prognosis. RESULTS: FLI1 is a potential radiosensitivity regulator which was dramatically overexpressed in the patients with PD to radiotherapy compared to those with CR. FLI1 induced radiotherapy resistance and enhanced the ability of DNA damage repair in vitro, and promoted radiotherapy resistance in vivo. Mechanistic investigations showed that FLI1 upregulated the transcription of TIE1 by binding to its promoter, thus activated the PI3K/AKT signaling pathway. A decrease in TIE1 expression restored radiosensitivity of NPC cells. Furthermore, NPC patients with high levels of FLI1 and TIE1 were correlated with poor prognosis. CONCLUSION: Our study has revealed that FLI1 regulates radiotherapy resistance of NPC through TIE1-mediated PI3K/AKT signaling pathway, suggesting that targeting the FLI1/TIE1 signaling pathway could be a potential therapeutic strategy to enhance the efficacy of radiotherapy in NPC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03986-y. BioMed Central 2023-02-22 /pmc/articles/PMC9945741/ /pubmed/36814284 http://dx.doi.org/10.1186/s12967-023-03986-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Enni
Huang, Jiajia
Chen, Miao
Wu, Jiawei
Ouyang, Puyun
Wang, Xiaonan
Shi, Dingbo
Liu, Zhiqiao
Zhu, Wancui
Sun, Haohui
Yang, Shanshan
Zhang, Baoyu
Deng, Wuguo
Qiu, Huijuan
Xie, Fangyun
FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
title FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
title_full FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
title_fullStr FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
title_full_unstemmed FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
title_short FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
title_sort fli1 regulates radiotherapy resistance in nasopharyngeal carcinoma through tie1-mediated pi3k/akt signaling pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945741/
https://www.ncbi.nlm.nih.gov/pubmed/36814284
http://dx.doi.org/10.1186/s12967-023-03986-y
work_keys_str_mv AT chenenni fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT huangjiajia fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT chenmiao fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT wujiawei fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT ouyangpuyun fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT wangxiaonan fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT shidingbo fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT liuzhiqiao fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT zhuwancui fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT sunhaohui fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT yangshanshan fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT zhangbaoyu fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT dengwuguo fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT qiuhuijuan fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway
AT xiefangyun fli1regulatesradiotherapyresistanceinnasopharyngealcarcinomathroughtie1mediatedpi3kaktsignalingpathway